Semperis Enhances the Industry’s Most Comprehensive Active Directory Protection Platform with Continuous Security Validation
4.5.2021 16:00:00 EEST | Business Wire | Press release
Semperis, the pioneer of identity-driven cyber resilience for enterprises, today announced the general availability of Directory Services Protector (DSP) v3.5, which includes DSP Intelligence, a new module that provides automated security assessments of Microsoft Active Directory (AD). DSP Intelligence proactively uncovers dangerous vulnerabilities that arise from external threat actors, systemic weaknesses in default identity and access settings, and even internal configuration drift that leads to security regression.
The company also announced enhancements to Active Directory Forest Recovery (ADFR), the only disaster recovery product for AD purpose-built to combat cyberattacks. New ADFR capabilities include unique backup set encryption keys, advanced forensics search, and extended support for SAML and MFA authentication.
The continuous security assessment capabilities now available in DSP Intelligence address the skyrocketing proliferation of cyberattacks—including the infamous SolarWinds supply-chain attack and the Hafnium attack on Microsoft Exchange—that target identity systems, especially AD. As the gatekeeper to critical applications and data in 90% of organizations worldwide, AD is a common access vector for attackers and extremely complex to secure given its constant flux, sheer number of settings, and the increasingly sophisticated threat landscape. Findings from companies using Semperis’ free Purple Knight security assessment tool revealed that even large organizations with significant investments in security resources are failing to close critical gaps in AD, scoring an average of 61%, with Kerberos authentication being the top risk area.
“Active Directory is a critical piece of most enterprises’ IT infrastructure but is notoriously difficult to keep secure,” said Darren Mar-Elia, Vice President of Products at Semperis. “Not only are its settings complex, but both AD itself and attack paths are constantly evolving. Organizations must be able to ensure their directory services are secure on a continual basis—not just at a point in time—while actively testing against the latest indicators for new attacks and threats. DSP Intelligence is designed to provide a larger range of security indicators and advance pre-attack tests to harden AD against new adversary TTPs and spot your weaknesses before attackers do. The threat hunting capabilities have also proven to be extremely helpful for organizations in post-breach scenarios to understand how attackers broke in and how to close backdoors for good.”
A growing number of breaches involve the exploitation of suboptimal AD configurations to allow attackers to gain a foothold within target networks, access sensitive resources, and deploy malware. To get ahead of attackers, DSP Intelligence continuously queries an organization’s AD environment and performs a comprehensive set of tests against the most common and effective attack vectors that correlate to known security frameworks such as the MITRE ATT&CK.
With the addition of DSP Intelligence, Semperis further establishes DSP as the industry’s most comprehensive AD threat detection and response platform. Semperis also updated the complementary modules, DSP Essential and DSP Advanced, which address foundational directory security and operational use cases:
- DSP Essential– AD change tracking and rollback
- DSP Advanced– Autonomous threat protection and response
- DSP Intelligence – Security validation and breach prevention
To see DSP Intelligence in action, watch the five-minute video overview: https://pages.semperis.com/dsp-intelligence-video-intro/
For more information about DSP and ADFR, visit the product pages below:
About Semperis
For security teams charged with defending hybrid and multi-cloud environments, Semperis ensures integrity and availability of critical enterprise directory services at every step in the cyber kill chain and cuts recovery time by 90%. Purpose-built for securing Active Directory, Semperis’ patented technology protects over 40 million identities from cyberattacks, data breaches, and operational errors. The world’s leading organizations trust Semperis to spot directory vulnerabilities, intercept cyberattacks in progress, and quickly recover from ransomware and other data integrity emergencies. Semperis is headquartered in New Jersey and operates internationally, with its research and development team distributed between San Francisco and Tel Aviv.
Semperis hosts the award-winning Hybrid Identity Protection conference (www.hipconf.com). The company has received the highest level of industry accolades and was recently ranked the fourth fastest-growing company in the tri-state area and 35th overall in Deloitte’s 2020 Technology Fast 500™. Semperis is accredited by Microsoft and recognized by Gartner.
Twitter
https://twitter.com/SemperisTech
LinkedIn
https://www.linkedin.com/company/semperis
Facebook
https://www.facebook.com/SemperisTech
YouTube
https://www.youtube.com/channel/UCycrWXhxOTaUQ0sidlyN9SA
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210504005043/en/
Contact information
Media Contact
Jessica MacGregor
fama PR for Semperis
Semperis@famapr.com
617-986-5024
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
